Jacqueline Buss
Primary Care · Quakertown, PANPI 1750941803
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.
Across 111 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$490
- Lilly USA, LLC$265
- Novo Nordisk$231
- Pfizer$198
- AstraZeneca$187
- Boehringer Ingelheim$172
- plus $711 from 15 others
What the payments were for
- Food & beverage$2,254100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $490 |
| Lilly USA, LLC | 12 | $265 |
| Novo Nordisk | 12 | $231 |
| Pfizer | 10 | $198 |
| AstraZeneca | 11 | $187 |
| Boehringer Ingelheim | 8 | $172 |
| GSK | 5 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $97 |
| Abbott | 4 | $87 |
| Astellas Pharma US Inc | 2 | $64 |
| Exact Sciences | 3 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Merck | 2 | $40 |
| Almatica Pharma LLC | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Dexcom, Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
How this compares
$2,254 in reported general payments places this provider in the 80th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 17 | $29,065 |
| OzempicSemaglutide | 14 | $13,464 |
| MounjaroTirzepatide | 11 | $10,371 |
| FarxigaDapagliflozin Propanediol | 12 | $6,925 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,920 |
| Lisdexamfetamine Dimesylate | 13 | $4,314 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,740 |
| Memantine Hcl | 13 | $2,211 |
| Levothyroxine Sodium | 137 | $2,021 |
| Atorvastatin Calcium | 151 | $1,875 |
| Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc | 18 | $1,760 |
| Pantoprazole Sodium | 54 | $968 |
| Lisinopril | 105 | $947 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $927 |
| Losartan Potassium | 80 | $915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $172 | $29,06517 claims |
| Novo NordiskOzempic | $231 | $13,46414 claims |
| Lilly USA, LLCMounjaro | $265 | $10,37111 claims |
| AstraZenecaFarxiga | $187 | $6,92512 claims |
| GSKBreo Ellipta | $144 | $6,92014 claims |
| AbbVieSynthroid | $490 | $72713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Quakertown
- Kersten ReiderMount Penn$121K
- Teresa GiamboyPhiladelphia$21K
- Nicole IlgenfritzBethel Park$18K
- Galyna VorokhibPhiladelphia$12K
- Melissa BeansWarrington$12K
- Mollie McGuireJohnstown$11K
- Andrea MauriceNew Cumberland$11K
- Kendell SoglieroSmithfield$9K
- Minjung RegerDoylestown$9K
- Mackenzie HouserMedia$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.